^
Association details:
| Biomarker: | HRAS mutation |
|---|---|
| Cancer: | Rhabdomyosarcoma |
| Drug: | Zarnestra (tipifarnib) (CXCL12 inhibitor, Farnesyl transferase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma
Published date:
04/22/2022
Excerpt:
In HRAS-mutant cell lines, tipifarnib reduced two-dimensional and three-dimensional cell growth, and in vivo treatment with tipifarnib resulted in tumor growth inhibition exclusively in HRAS-mutant RMS xenografts.
DOI:
10.1038/s41388-022-02305-x
Source:
Title:
Inhibition of farnesyl transferase by tipifarnib leads to cell growth inhibition in HRAS-mutated human rhabdomyosarcoma
Published date:
10/27/2020
Excerpt:
Rhabdomyosarcoma (RMS)...Cell cycle progression is halted in the presence of tipifarnib in HRAS mutated cell lines. In vivo exposure to tipifarnib in HRAS-mutated RMS xenografts results in tumor growth inhibition.
